211 related articles for article (PubMed ID: 10730906)
1. Changes in neoplastic cell features and sensitivity to mitotane during mitotane-induced remission in a patient with recurrent, metastatic adrenocortical carcinoma.
Seki M; Nomura K; Hirohara D; Kanazawa M; Sawada T; Takasaki K; Demura H
Endocr Relat Cancer; 1999 Dec; 6(4):529-33. PubMed ID: 10730906
[TBL] [Abstract][Full Text] [Related]
2. Rapid and Complete Remission of Metastatic Adrenocortical Carcinoma Persisting 10 Years After Treatment With Mitotane Monotherapy: Case Report and Review of the Literature.
El Ghorayeb N; Rondeau G; Latour M; Cohade C; Olney H; Lacroix A; Perrotte P; Sabourin A; Mazzuco TL; Bourdeau I
Medicine (Baltimore); 2016 Mar; 95(13):e3180. PubMed ID: 27043680
[TBL] [Abstract][Full Text] [Related]
3. [Mitotane in the treatment of adrenal carcinoma].
Sane T
Duodecim; 2010; 126(17):2040-6. PubMed ID: 21053521
[TBL] [Abstract][Full Text] [Related]
4. Comparison of two mitotane starting dose regimens in patients with advanced adrenocortical carcinoma.
Kerkhofs TM; Baudin E; Terzolo M; Allolio B; Chadarevian R; Mueller HH; Skogseid B; Leboulleux S; Mantero F; Haak HR; Fassnacht M
J Clin Endocrinol Metab; 2013 Dec; 98(12):4759-67. PubMed ID: 24057287
[TBL] [Abstract][Full Text] [Related]
5. [Therapy of the adrenocortical carcinoma with Lysodren (o,p'-DDD). Therapeutic management by monitoring o,p'-DDD blood levels].
Heilmann P; Wagner P; Nawroth PP; Ziegler R
Med Klin (Munich); 2001 Jul; 96(7):371-7. PubMed ID: 11494911
[TBL] [Abstract][Full Text] [Related]
6. Complete Responses to Mitotane in Metastatic Adrenocortical Carcinoma-A New Look at an Old Drug.
Reidy-Lagunes DL; Lung B; Untch BR; Raj N; Hrabovsky A; Kelly C; Gerst S; Katz S; Kampel L; Chou J; Gopalan A; Saltz LB
Oncologist; 2017 Sep; 22(9):1102-1106. PubMed ID: 28559412
[TBL] [Abstract][Full Text] [Related]
7. Is there a role for low doses of mitotane (o,p'-DDD) as adjuvant therapy in adrenocortical carcinoma?
Dickstein G; Shechner C; Arad E; Best LA; Nativ O
J Clin Endocrinol Metab; 1998 Sep; 83(9):3100-3. PubMed ID: 9745410
[TBL] [Abstract][Full Text] [Related]
8. Association of mitotane with chylomicrons and serum lipoproteins: practical implications for treatment of adrenocortical carcinoma.
Kroiss M; Plonné D; Kendl S; Schirmer D; Ronchi CL; Schirbel A; Zink M; Lapa C; Klinker H; Fassnacht M; Heinz W; Sbiera S
Eur J Endocrinol; 2016 Mar; 174(3):343-53. PubMed ID: 26671975
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant mitotane treatment for adrenocortical carcinoma.
Terzolo M; Angeli A; Fassnacht M; Daffara F; Tauchmanova L; Conton PA; Rossetto R; Buci L; Sperone P; Grossrubatscher E; Reimondo G; Bollito E; Papotti M; Saeger W; Hahner S; Koschker AC; Arvat E; Ambrosi B; Loli P; Lombardi G; Mannelli M; Bruzzi P; Mantero F; Allolio B; Dogliotti L; Berruti A
N Engl J Med; 2007 Jun; 356(23):2372-80. PubMed ID: 17554118
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant mitotane in adrenocortical carcinoma.
Dickstein G; Shechner C; Nativ O
N Engl J Med; 2007 Sep; 357(12):1257-8; author reply 1259. PubMed ID: 17891838
[No Abstract] [Full Text] [Related]
11. [Normalisation of contralateral adrenal function after long-term mitotane therapy in a girl after surgical treatment of adrenocortical carcinoma].
Lecka A; Ginalska-Malinowska M
Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw; 2006; 12(3):234-6. PubMed ID: 17020662
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant mitotane in adrenocortical carcinoma.
Lee JE
N Engl J Med; 2007 Sep; 357(12):1258; author reply 1259. PubMed ID: 17891836
[No Abstract] [Full Text] [Related]
13. Adjuvant mitotane in adrenocortical carcinoma.
Bertherat J; Coste J; Bertagna X
N Engl J Med; 2007 Sep; 357(12):1256-7; author reply 1259. PubMed ID: 17881760
[No Abstract] [Full Text] [Related]
14. Successful treatment of adrenocortical carcinoma with pulmonary metastasis in a child: report of a case.
Arai H; Rino Y; Yamanaka S; Yukawa N; Wada N; Kato H; Yanagimachi M; Goto H; Oshiro H; Yamanaka S; Inayama Y; Lee J; Masuda M
Surg Today; 2008; 38(10):965-9. PubMed ID: 18820878
[TBL] [Abstract][Full Text] [Related]
15. Risk of adrenocortical carcinoma in adrenal tumours greater than 8 cm.
Abdel-Aziz TE; Rajeev P; Sadler G; Weaver A; Mihai R
World J Surg; 2015 May; 39(5):1268-73. PubMed ID: 25526921
[TBL] [Abstract][Full Text] [Related]
16. Functioning and nonfunctioning adrenocortical carcinoma: clinical presentation and therapeutic strategies.
Demeure MJ; Somberg LB
Surg Oncol Clin N Am; 1998 Oct; 7(4):791-805. PubMed ID: 9735134
[TBL] [Abstract][Full Text] [Related]
17. Pregnancy in a patient with adrenocortical carcinoma during treatment with Mitotane - a case report.
Baszko-Błaszyk D; Ochmańska K; Waśko R; Sowiński J
Endokrynol Pol; 2011; 62(2):186-8. PubMed ID: 21528483
[TBL] [Abstract][Full Text] [Related]
18. Pregnancy in a patient with adrenal carcinoma treated with mitotane: a case report and review of literature.
Tripto-Shkolnik L; Blumenfeld Z; Bronshtein M; Salmon A; Jaffe A
J Clin Endocrinol Metab; 2013 Feb; 98(2):443-7. PubMed ID: 23275528
[TBL] [Abstract][Full Text] [Related]
19. The combination of insulin-like growth factor receptor 1 (IGF1R) antibody cixutumumab and mitotane as a first-line therapy for patients with recurrent/metastatic adrenocortical carcinoma: a multi-institutional NCI-sponsored trial.
Lerario AM; Worden FP; Ramm CA; Hesseltine EA; Stadler WM; Else T; Shah MH; Agamah E; Rao K; Hammer GD
Horm Cancer; 2014 Aug; 5(4):232-9. PubMed ID: 24849545
[TBL] [Abstract][Full Text] [Related]
20. [A CASE REPORT: A PATIENT WITH METASTATIC ADRENOCORTICAL CARCINOMA EXCLUSIVELY TREATED WITH MITOTANE WITH LONG-TERM FOLLOW-UP].
Yamashita D; Hanai T; Onuki T; Suzuki K; Nakayama T
Nihon Hinyokika Gakkai Zasshi; 2019; 110(1):12-17. PubMed ID: 31956212
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
